Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;22(1):1-8.
doi: 10.5021/ad.2010.22.1.1. Epub 2010 Feb 28.

Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases

Kee Suck Suh  1 , Jin Seuk Kang, Jae Woo Baek, Tae Kwon Kim, Jin Woo Lee, Young Seung Jeon, Min Soo Jang, Sang Tae Kim
Affiliations

Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases

Kee Suck Suh et al. Ann Dermatol. 2010 Feb.

Abstract

Background: Ultraviolet (UV) radiation has been used for decades to treat a variety of skin diseases. UVA1 was used initially as an effective treatment for acute exacerbated atopic dermatitis. Since then, UVA1 has been attempted for recalcitrant skin diseases.

Objective: This study examined the efficacy of UVA1 phototherapy in three recalcitrant skin diseases.

Methods: This retrospective study reviewed the efficacy and follow-up of 26 patients with atopic dermatitis (AD), mycosis fungoides (MF) and localized scleroderma (LS). SUPUVASUN 3000 (Mutzhas Co., Munich, Germany) and SELLAMED 3000 (Sellas Medizinische Gerate GmbH, Gevelsberg, Germany) were the UVA1 equipment used. Irradiation was performed in accordance with the disease. Low-dose (20 J/cm(2)), medium-dose (65 J/cm(2)) and high-dose regimens (100 J/cm(2)) of UVA1 therapy were employed. The frequency of the therapy ranged from 3 to 5 times weekly. The therapeutic effectiveness was assessed according to the clinical examination before and after the last treatment.

Results: In patients with AD, complete and partial remission was achieved in four (80%) and one (20%) patient, respectively. In patients with MF, complete and partial remission was observed in thirteen (86.7%) and two (13.3%) patients, respectively. In patients with LS, complete and partial remission was observed in three (50%) and three (50%) patients, respectively.

Conclusion: UVA1 phototherapy is an effective treatment modality for acute exacerbated AD, MF and LS.

Keywords: Recalcitrant skin disease; UVA1.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Atopic dermatitis lesions (A) before and (B) after 11 irradiations with 100 J/cm2 UVA1 phototherapy.
Fig. 2
Fig. 2
Solitary mycosis fungoides lesion (A) before and (B) after 15 irradiations with 65 J/cm2 UVA1 phototherapy.
Fig. 3
Fig. 3
Mycosis fungoides lesions (A) before and (B) after 22 irradiations with 100 J/cm2 UVA1 phototherapy.
Fig. 4
Fig. 4
Localized scleroderma lesion (A) before and (B) after 86 irradiations with 100 J/cm2 UVA1 phototherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med. 1997;186:1763–1768. - PMC - PubMed
    1. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet. 1997;350:1295–1296. - PubMed
    1. Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet. 1994;343:25–26. - PubMed
    1. Grabbe J, Welker P, Humke S, Grewe M, Schopf E, Henz BM, et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol. 1996;107:419–422. - PubMed
    1. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981;77:13–19. - PubMed